<DOC>
	<DOCNO>NCT00650949</DOCNO>
	<brief_summary>This study seek ( ) determine safe dose CYT997 give combination carboplatin patient relapse glioblastoma multiforme ( glioma ) ( ii ) determine whether combination CYT997 carboplatin useful treatment glioma .</brief_summary>
	<brief_title>Efficacy Study CYT997 Combination With Carboplatin Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must histologicallyconfirmed glioblastoma multiforme progress initial surgery , radiation therapy temozolomide chemotherapy . Measurable tumour must present gadoliniumenhanced MRI At least 3 month must elapse complete radiation minimize possibility pseudoprogression . At least 4 week since prior chemotherapy ( 6 week last regimen include bischloroethylnitrosourea ( BCNU ) ChloroethylCyclohexylNitrosoUrea ( CCNU ) ) . Age ≥ 18 year . If patient take steroid , dose must stable = 7 day . Eastern Cooperative Oncology Group ( ECOG ) performance status = 2 . Life expectancy great 2 month . Patients must adequate organ marrow function define : Absolute neutrophil count = 1.5 × 109/L Platelet count = 100 × 109/L Total bilirubin within normal limit Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 5 × upper limit normal ( ULN ) Creatinine within normal limit OR creatinine clearance = 60 mL/min/1.73 m2 patient creatinine level normal Normal leave ventricular ejection fraction gate blood pool scan echocardiogram Must agree use adequate contraceptive measure indicate Ability understand willingness sign write informed consent document Patients receive investigational agent precede four week prior commence therapy study . Patients previously treat carboplatin . Patients previously treat bevacizumab antiangiogenesis vasculardisrupting agent Patients receive enzymeinducing anticonvulsant drug ( EIACD ) phenytoin carbamazepine . Patients history allergic reaction attribute compound similar chemical composition CYT997 agent use study . Patients uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , cardiac arrhythmia psychiatric illness/social situation would limit compliance study requirement . Pregnant lactating woman . Patients immune deficiency , include HIVpositive patient . Patients uncontrolled diarrhoea despite optimal medication history acute gastrointestinal bleeding . Patients unable unwilling undergo MRI scan Patients follow conditions/treatments exclude : Myocardial infarction ( MI ) stroke within 6 month History stroke transient ischemic attack ( TIAs ) Unstable angina pectoris acute ischemic change ECG History diabetic retinopathy Symptomatic peripheral arterial disease Major surgery last 4 week Evidence intratumoural haemorrhage imaging , except stable grade1 postoperative haemorrhage . Current therapeutic anticoagulation warfarin heparin ( excludes lowdose prophylactic heparin ) . Uncontrolled hypertension The need antiarrhythmic drug Presence luminal stenosis 50 % extracranial intracranial artery supply brain , measure magnetic resonance angiography ( MRA ) baseline . Patients baseline prolongation QTc interval Common Terminology Criteria ( CTC ) grade 1 ( QTc &gt; 0.45 0.47 sec ) great . Patients impaired cardiac function clinically significant cardiac disease , include one following : Left ventricular ejection fraction ( LVEF ) &lt; 45 % determine multigated acquisition ( MUGA ) scan echocardiogram ; complete leave bundle branch block ; obligate use cardiac pacemaker ; congenital long QT syndrome ; history presence ventricular tachyarrhythmia ; presence unstable atrial fibrillation ( ventricular response &gt; 100 bpm ) Patients stable atrial fibrillation eligible , provide meet cardiac exclusion criterion ; clinically significant rest bradycardia ( &lt; 50 bpm ) ; right bundle branch block + leave anterior hemiblock ( bifascicular block ) ; angina pectoris = 3 month prior start study drug ; acute MI = 3 month prior start study drug ; clinically significant heart disease ( e.g. , congestive heart failure ( CHF ) , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) . Patients currently receive treatment medication know prolong QTc interval and/or induce Torsades de Pointes arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Glioma</keyword>
	<keyword>Phase Ib/II</keyword>
	<keyword>CYT997</keyword>
</DOC>